Pharmaceutical

Adamis Pharmaceuticals announced its proposed presentation for the American Academy of Allergy, Asthma, and Immunology joint congress with the World Allergy Organization was approved.

Adamis Pharmaceuticals (NASDAQ:ADMP) announced its proposed presentation for the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization was approved.
As quoted in the press release:

Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi was studied in trained and untrained adults, adolescents and caregivers. The results definitively showed Symjepi to be an easy to use, small and intuitive device.” Dr. Ronald Moss, Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For a layperson, treatment of anaphylaxis with a simple non-threatening device is critical to successful use.” The presentation will focus on the successful human factors study utilizing Symjepi.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1816.18-2.38
Silver20.81-0.01
Copper3.77-0.01
Palladium1912.50+43.50
Platinum927.50+17.50
Oil112.23+0.47
Heating Oil4.03-0.09
Natural Gas6.77+0.20

DOWNLOAD FREE REPORTS

×